Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer
Author(s): Yen-Shen Lu, MD, PhD1; Eznal Izwadi Bin Mohd Mahidin, MD2; Hamdy Azim, MD3; Yesim Eralp, MD4; Yoon Sim Yap, MD, PhD5; Seock-Ah Im, MD, PhD6; Julie Rihani7; Erhan Gokmen, MD, PhD8; Ahmed El Bastawisy, MD9; Nuri Karadurmus, MD10; Yueh Ni Lim, MD11; Chun Sen Lim, MD12; K. Govind Babu, MD13; Konstantin Penkov, MD14; James Bowles, BMedSci15; Teresa Delgar Alfaro, Pharm D, MsC15; Jiwen Wu, PhD16; Melissa Gao, MD, PhD15; Khemaies Slimane, MD15; Nagi S. El Saghir, MD ns23@aub.edu.lb17; Le Thanh Duc, MD18; Wei-Pang Chung, MD19
Source: https://doi.org/10.1200/JCO.24.00144
Dr. Anjan Patel's Thoughts
Nicely done study comparing Ribociclib + ET vs chemotherapy in premenopausal high-risk HR+, HER2-neg patients felt to be high risk. Results showed better efficacy (PFS), tolerability and similar response rates. Of note, >80% of patients had visceral disease or were felt to be rapid progressors. Anti-hormone-based therapy remains king in the HR+ setting.
PURPOSE
A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC).
PATIENTS AND METHODS
In this open-label, multi-center, randomized phase 2 trial, pre/perimenopausal women with clinically aggressive HR+/HER2− ABC were randomized 1:1 to first-line ribociclib (600 mg daily; 3-weeks-on, 1-week-off) plus letrozole/anastrozole and goserelin or investigator’s choice of combination CT (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine). The primary endpoint was progression-free survival (PFS).
RESULTS
Among 222 patients randomized to ribociclib plus ET (n=112) or combination CT (n=110), 150 (67.6%) had symptomatic visceral metastases, 41 (18.5%) had rapid disease progression per investigator’s judgment, and 31 (14.0%) had symptomatic non-visceral disease. Overall, 106 (47.7%) patients had investigator-assessed visceral crisis. Median follow-up time was 37.0 months. At data cutoff, 31.3% (ribociclib arm) and 15.5% (CT arm) of patients had completed study treatment and transitioned to post-trial access. The median PFS was 21.8 months (ribociclib plus ET; 95% CI, 17.4-26.7 months) and 12.8 months (combination CT; 95% CI, 10.1-18.4 months); hazard ratio [HR], 0.61; 95% CI, 0.43-0.87; P=.003. The overall response rates and the median time to response in the ribociclib versus CT arms, respectively, were 66.1% and 61.8% and 4.9 months and 3.2 months (HR, 0.76; 95% CI, 0.55-1.06). Lower rates of symptomatic adverse events were observed in the ribociclib versus CT arm
CONCLUSIONS
First-line ribociclib plus ET showed a significant PFS benefit, similar response rates, and better tolerability over combination CT in patients with clinically aggressive HR+/HER2− ABC.
Author Affiliations
1National Taiwan University Hospital, Taipei, Taiwan; 2Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; 3School of Medicine, Cairo University, Cairo, Egypt; 4Acıbadem Research Institute of Senology, Acıbadem University, Istanbul, Turkey; 5National Cancer Centre Singapore, Singapore; 6Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; 7Independent Patient Advocate, Amman, Jordan; 8Ege University Faculty of Medicine, Izmir, Turkey; 9National Cancer Institute, Cairo University, Egypt; 10Gülhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey; 11Sarawak General Hospital, Kuching, Sarawak, Malaysia; 12Hospital Sultan Ismail, Johor Bharu, Johor Darul Ta’zim, Malaysia; 13HCG Curie Centre of Oncology and Kidwai Memorial Institute of Oncology, Bangalore, India; 14Private Medical Institution Euromedservice, St Petersburg, Russian Federation; 15Novartis Pharma AG, Basel, Switzerland; 16Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 17American University of Beirut Medical Center, Beirut, Lebanon; 18National Cancer Hospital, Hanoi, Vietnam; 19National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;Related Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
